This Migraine Condition Affects 1 in 3 Women. A Treatment Just Met a Phase 3 Goal
Atogepant just met a late-stage study goal. Researchers say the results could help prevent an all-too-common condition that impacts millions of women.
We haven't written up this one. Inc. has the full story — the link below goes straight to it.